Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

UK scientists say further easing of COVID rules won't overwhelm health service

Published 04/05/2021, 11:08 AM
Updated 04/05/2021, 11:10 AM
© Reuters. A woman jogs through Hyde Park, amid the coronavirus disease (COVID-19) outbreak, in London

LONDON (Reuters) - The next step to ease COVID-19 lockdown restrictions in England is not expected to put unsustainable pressure on the health service even if it results in an uptick of COVID-19 infections, scientists advising the government said on Monday.

However, the scientists said that a resurgence in hospitalisations and deaths at some point was still highly likely, though its scale and timing was uncertain.

British Prime Minister Boris Johnson is expected to announce later on Monday that England can proceed to Stage 2 of his roadmap out of lockdown, allowing hospitality to re-open outdoors next week and the restart of all retail.

The Scientific Advisory Group for Emergencies (SAGE), which advises the government, said that the move would not overwhelm the state-run National Health Service (NHS) even if infections rose assuming the country's successful vaccine programme stays on track.

"Any resurgence in hospital admissions and deaths following Step 2 of the Roadmap alone is highly unlikely to put unsustainable pressure on the NHS," SAGE said in the minutes of a March 29 meeting, published on Monday.

SAGE cited work compiled by the Scientific Pandemic Influenza Group on Modelling (SPI-M), which looked at models made by Imperial College London, Warwick University and the London School of Hygiene and Tropical Medicine.

SPI-M said that a new peak could occur in summer or autumn, and that its timing and size would depend on how people behave after restrictions end.

Whether England can proceed to steps 3 and 4 of lockdown easing, which could see formal restrictions on social contact end in June, will depend on data following each step.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"It is highly likely that there will be a further resurgence in hospitalisations and deaths after the later steps of the Roadmap," SPI-M said in a paper published on Monday.

Most scenarios saw any new peak as smaller than the one in January 2021 but more pessimistic assumptions about transmission reduction and vaccine effectiveness "can result in resurgences in hospitalisations of a similar scale to January 2021."

The modelling did not account for the possible emergence of vaccine-escaping variants or looser travel rules.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.